Executive Order Restricts Cell Export to Foreign Labs On June 18, 2025, the U.S. FDA suspended certain new clinical trials involving the transfer of American citizens' living cells to six designated "countries of concern" for ex vivo genetic engineering and subsequent re-administration in the United States. Framed as a biosecurity and patient safety measure, the [...]